Abstract: Methods of improving subjective sleep efficiency, reducing subjective sleep onset latency, and/or reducing subjective wake after sleep onset in subjects comprising administering to the subject 5 mg or 10 mg of lemborexant or an equivalent dose of a pharmaceutically acceptable salt thereof are disclosed herein. Also disclosed herein is lemborexant or a pharmaceutically acceptable salt thereof for use in improving subjective sleep efficiency, reducing subjective sleep onset latency, and/or reducing subjective wake after sleep onset in a subject comprising administering to the subject 5 mg or 10 mg of lemborexant or an equivalent dose of a pharmaceutically acceptable salt thereof.

Abstract: Provided herein are methods of reducing clinical decline in a subject having early Alzheimer's disease, methods of converting an amyloid positive subject having early Alzheimer's disease to amyloid negative, methods of reducing brain amyloid level in a subject, and methods of preventing Alzheimer's disease, the methods comprising administering a composition comprising a therapeutically effective amount of at least one anti-A? protofibril antibody. In some embodiments, the subject is ApoE4-positive. In some embodiments, the at least one anti-A? protofibril antibody is BAN2401.